29 March 2017 - A push by the EMA to speed up the approval of new drugs that show promise is running into resistance from some of the national agencies that will ultimately decide whether the medicines are worth buying.

Pharmaceutical companies, patient advocacy groups and lawmakers around the world are pushing regulators to cut through what they see as red tape and adopt more streamlined approval processes for new drugs.

Europe has been looking at new approaches to drug testing for several years and the issue came to the fore again in January after U.S. President Donald Trump vowed to accelerate approvals to get new drugs to patients faster.

Read Daily Mail article